Shares of Cantel Medical Corp. (NYSE:CMD) have received a consensus broker rating score of 2.25 (Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. Cantel Medical’s rating score has improved by 10% in the last three months as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a one year consensus price target of $115.00 for the company and are predicting that the company will post $0.58 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Cantel Medical an industry rank of 174 out of 265 based on the ratings given to related companies.
Shares of Cantel Medical (CMD) opened at $110.18 on Friday. The stock has a market capitalization of $4,606.19, a P/E ratio of 51.49 and a beta of 1.25. The company has a current ratio of 2.44, a quick ratio of 1.48 and a debt-to-equity ratio of 0.31. Cantel Medical has a 12-month low of $69.21 and a 12-month high of $110.74.
In other news, EVP Eric W. Nodiff sold 2,868 shares of the stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $97.55, for a total value of $279,773.40. Following the completion of the sale, the executive vice president now directly owns 39,102 shares of the company’s stock, valued at $3,814,400.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.30% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. First Trust Advisors LP lifted its position in Cantel Medical by 6.8% in the third quarter. First Trust Advisors LP now owns 11,677 shares of the company’s stock worth $1,100,000 after purchasing an additional 739 shares during the period. Rhumbline Advisers lifted its position in Cantel Medical by 1.2% in the third quarter. Rhumbline Advisers now owns 76,496 shares of the company’s stock worth $7,204,000 after purchasing an additional 870 shares during the period. Aperio Group LLC lifted its position in Cantel Medical by 8.4% in the third quarter. Aperio Group LLC now owns 13,894 shares of the company’s stock worth $1,308,000 after purchasing an additional 1,075 shares during the period. Globeflex Capital L P bought a new position in Cantel Medical in the second quarter worth $114,000. Finally, American International Group Inc. lifted its position in Cantel Medical by 5.4% in the third quarter. American International Group Inc. now owns 28,684 shares of the company’s stock worth $2,701,000 after purchasing an additional 1,464 shares during the period. 85.20% of the stock is owned by institutional investors.
Cantel Medical Company Profile
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.